MMP9 and central nervous system cancer: SRGN and several inflammatory molecules and proteolytic enzymes and inhibitors including TGFβ1, TGFβRI, IL-8, CCL-2, IL-1β, chemokine (C-X-C motif) ligand 1 (CXCL-1), IL-6, CCL-20, CXCR-2, matrix metalloproteinase 14 (MMP-14), matrix metalloproteinase 9 (MMP-9), matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 1 (MMP-1), urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) are highly expressed in GBM compared to low-grade gliomas (LGG) and non-tumor brain tissues (Figure 1B and Table S2).